Cargando…

Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions

BACKGROUND: Tiotropium is reimbursed since March 2004 in Belgium for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Questions however remain on this product's value for money. The purpose of this study is to calculate tiotropium's cost-effectiveness under real-world conditi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neyt, Mattias, Devriese, Stephan, Thiry, Nancy, Van den Bruel, Ann
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2954895/ https://www.ncbi.nlm.nih.gov/pubmed/20843311 http://dx.doi.org/10.1186/1471-2466-10-47

Ejemplares similares

Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis
por: Van den Bruel, Ann, et al.
Publicado: (2010)

First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis
por: Neyt, Mattias, et al.
Publicado: (2018)

A cost-utility analysis of transcatheter aortic valve implantation in Belgium: focusing on a well-defined and identifiable population
por: Neyt, Mattias, et al.
Publicado: (2012)

Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China
por: Lan, Ying, et al.
Publicado: (2023)

Cost-effectiveness of cardiac resynchronisation therapy for patients with moderate-to-severe heart failure: a lifetime Markov model
por: Neyt, Mattias, et al.
Publicado: (2011)

Tiotropium Add-On and Treatable Traits in Asthma-COPD Overlap: A Real-World Pilot Study
por: Ishiura, Yoshihisa, et al.
Publicado: (2022)

Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients
por: Miravitlles, Marc, et al.
Publicado: (2016)

The cost-utility of catheter ablation of atrial fibrillation: a systematic review and critical appraisal of economic evaluations
por: Neyt, Mattias, et al.
Publicado: (2013)

Role of tiotropium in the treatment of COPD
por: Rice, Kathryn L, et al.
Publicado: (2007)

Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD
por: Pelaia, Girolamo, et al.
Publicado: (2015)

Characterizing Real-World Use Of Tiotropium In Asthma In The USA
por: Averell, Carlyne M, et al.
Publicado: (2019)

Assessment of physical functioning and handling of tiotropium/olodaterol Respimat(®) in patients with COPD in a real-world clinical setting
por: Steinmetz, Karl-Otto, et al.
Publicado: (2019)

Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium–olodaterol for patients with COPD in the Netherlands
por: van Boven, Job FM, et al.
Publicado: (2016)

Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)

Real-world effectiveness of early intervention with fixed-dose tiotropium/olodaterol vs tiotropium in Japanese patients with COPD: a high-dimensional propensity score–matched cohort analysis
por: Muro, Shigeo, et al.
Publicado: (2021)

Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study
por: Ichinose, Masakazu, et al.
Publicado: (2018)

Correction to: Tiotropium/Olodaterol: A Review in COPD
por: Blair, Hannah A.
Publicado: (2019)

Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study [Corrigendum]
Publicado: (2018)

Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy
por: Palli, Swetha R., et al.
Publicado: (2020)

Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis
por: Neyt, Mattias, et al.
Publicado: (2014)

UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD
por: Tebboth, Abigail, et al.
Publicado: (2016)

Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History
por: Sethi, Sanjay, et al.
Publicado: (2023)

Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
por: Zafari, Zafar, et al.
Publicado: (2018)

Trend of cost and utilization of COPD medication in Korea
por: Lee, Jongmin, et al.
Publicado: (2016)

Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD
por: Maltais, François, et al.
Publicado: (2019)

The real-world cost-effectiveness of bariatric surgery for the treatment of severe obesity: a cost–utility analysis
por: Lester, Erica L.W., et al.
Publicado: (2021)

Effect of add-on therapy of tiotropium in COPD treated with theophylline
por: Kawayama, Tomotaka, et al.
Publicado: (2008)

Socioeconomic gradients in tiotropium use among adults with COPD
por: Blanc, Paul D, et al.
Publicado: (2008)

The effect of tiotropium therapy on markers of elastin degradation in COPD
por: Ma, Shuren, et al.
Publicado: (2009)

Safety, tolerability and risk benefit analysis of tiotropium in COPD
por: Oba, Yuji, et al.
Publicado: (2008)

Efficacy of tiotropium–olodaterol fixed-dose combination in COPD
por: Derom, Eric, et al.
Publicado: (2016)

Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies
por: Singh, Dave, et al.
Publicado: (2016)

Preventing and managing exacerbations in COPD – critical appraisal of the role of tiotropium
por: Tashkin, Donald P
Publicado: (2010)

Tiotropium HandiHaler(®) in the treatment of COPD: A safety review
por: Kesten, Steven, et al.
Publicado: (2009)

Use of tiotropium in patients with COPD aged 80 years and older
por: SATOH, HIROAKI, et al.
Publicado: (2013)

Quality of life and adherence to inhaled corticosteroids and tiotropium in COPD are related
por: Koehorst-ter Huurne, Kirsten, et al.
Publicado: (2016)

Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective
por: Shah, Dhvani, et al.
Publicado: (2018)

Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease
por: Naik, Shalini, et al.
Publicado: (2010)

Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease
por: Chatterjee, Arjun, et al.
Publicado: (2012)

Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities
por: Kalhan, Ravi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4r8jo1iq8f7sldk9ao00b5rj6k